Keros gains FDA orphan drug status for DMD treatment KER-065
Keros Therapeutics has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational therapy KER-065…
Other Diseases
-
-
Boehringer and AnGes link on drug substance manufacture for PAD
Boehringer Ingelheim has entered a contract development and manufacturing agreement for the drug substance of AnGes' investigational therapy targeting peripheral…
-
āshibio licences vantictumab for rare bone disorder
Biotechnology company āshibio has entered an exclusive licencing agreement with Mereo BioPharma for the monoclonal antibody, vantictumab, to treat a…
-
Merck announces EC approval of Ogsiveo for desmoid tumours
The European Commission (EC) has granted marketing authorisation to SpringWorks Therapeutics, a subsidiary of Merck KGaA, for Ogsiveo (nirogacestat) to…
-
Aquestive signs $75m agreement for launch of Anaphylm
Aquestive Therapeutics has made a strategic funding agreement worth $75m with RTW Investments to support the potential launch of Anaphylm…
-
AbbVie expands North Chicago API production with $195m investment
AbbVie is investing $195m to strengthen domestic active pharmaceutical ingredient (API) production within the US, with the expansion of its…
-
MAXONA Pharma seeks FDA approval for pain relief MAX-001
MAXONA Pharmaceuticals has submitted an investigational new drug (IND) application seeking approval from the US Food and Drug Administration (FDA)…
-
CorMedix signs agreement to acquire Melinta for $300m
CorMedix, a biopharmaceutical company specialising in critical care products, has signed an agreement to acquire Melinta Therapeutics for $300m upfront.…
-
Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain…
-
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi
Arrowhead Pharmaceuticals’ subsidiary Visirna Therapeutics has entered an asset purchase agreement with Sanofi for the rights to develop and commercialise…
